Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)

Launched by UNIVERSITY OF VIRGINIA · Mar 18, 2019

Keywords

ClinConnect Summary

This clinical trial, called ZQL007, is studying how exercise and the medication liraglutide can help improve blood flow and insulin sensitivity in people with Type 2 diabetes. The researchers want to find out if doing exercise alone, taking liraglutide alone, or combining both approaches will increase blood flow in the heart and muscles, and help insulin work better in the body. Participants will be divided into three groups based on the treatment they receive, and they will be monitored for 16 weeks to see how these interventions affect their health.

To be part of this study, participants need to be between 21 and 60 years old, have a specific level of blood sugar control (an A1C of 8.5% or lower), and must not have used certain diabetes medications before. They should also be stable on their current diabetes medications for at least four months. However, individuals who are pregnant, have certain health conditions like heart disease, or have recently smoked are not eligible. If you join the trial, you can expect regular check-ups and support from the research team throughout the 16 weeks. This study is currently looking for participants, so it could be a great opportunity for those who qualify!

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 21-60
• • A1C ≤ 8.5%
• • Never on GLP-1RA (eg: exenatide, liraglutide) or DPP4I ( eg: Sitaglipton)
• • On stable dose of oral hypoglycemic agents \>4 months
• • On stable dose of other medications for \>4 months
• Exclusion Criteria:
• • Taking Insulin
• • Smoking presently or in the past 6 months
• • BP \>160/90
• • BMI \>35
• • Family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome
• • History of congestive heart failure, ischemic heart disease, severe pulmonary disease, liver or kidney disease.
• • Any vascular disease such as myocardial infarction, stroke, peripheral vascular disease
• • Presence of an intracardiac or intrapulmonary shunt (we will screen for this by auscultation during the physical exam by PI).
• • Pregnant or breastfeeding.
• • Known hypersensitivity to perflutren (contained in Definity)